Induced pluripotent stem cell

Last updated

Confocal microscopic image of a colony of human induced pluripotent stem cells derived from a patient with oculocutaneous albinism. Red indicates transcription factor Oct-4, green the protein SSEA4, and blue the nuclei of the cells. Human induced pluripotent stem cell colony (51816035910).jpg
Confocal microscopic image of a colony of human induced pluripotent stem cells derived from a patient with oculocutaneous albinism. Red indicates transcription factor Oct-4, green the protein SSEA4, and blue the nuclei of the cells.
Human iPS cells colonies. The spindle-shaped cells in the background are mouse fibroblast cells. Only those cells comprising the center colony are human iPS cells. Human iPS cells colonies.png
Human iPS cells colonies. The spindle-shaped cells in the background are mouse fibroblast cells. Only those cells comprising the center colony are human iPS cells.

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from a somatic cell. The iPSC technology was pioneered by Shinya Yamanaka and Kazutoshi Takahashi in Kyoto, Japan, who together showed in 2006 that the introduction of four specific genes (named Myc, Oct3/4, Sox2 and Klf4), collectively known as Yamanaka factors, encoding transcription factors could convert somatic cells into pluripotent stem cells. [1] Shinya Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent." [2]

Contents

Pluripotent stem cells hold promise in the field of regenerative medicine. [3] Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

The most well-known type of pluripotent stem cell is the embryonic stem cell. However, since the generation of embryonic stem cells involves destruction (or at least manipulation) [4] of the pre-implantation stage embryo, there has been much controversy surrounding their use. Patient-matched embryonic stem cell lines can now be derived using somatic cell nuclear transfer (SCNT).[ citation needed ]

Since iPSCs can be derived directly from adult tissues, they not only bypass the need for embryos, but can be made in a patient-matched manner, which means that each individual could have their own pluripotent stem cell line. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection. While the iPSC technology has not yet advanced to a stage where therapeutic transplants have been deemed safe, iPSCs are readily being used in personalized drug discovery efforts and understanding the patient-specific basis of disease. [5]

Yamanaka named iPSCs with a lower case "i" due to the popularity of the iPod and other products. [6] [7] [8] [9]

In his Nobel seminar, Yamanaka cited the earlier seminal work of Harold Weintraub on the role of myoblast determination protein 1 (MyoD) in reprogramming cell fate to a muscle lineage as an important precursor to the discovery of iPSCs. [10]

Production

A scheme of the generation of induced pluripotent stem (IPS) cells. (1) Isolate and culture donor cells. (2) Transduce stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3) Harvest and culture the cells according to ES cell culture, using mitotically inactivated feeder cells (lightgray). (4) A small subset of the transfected cells become iPS cells and generate ES-like colonies. Induction of iPS cells.svg
A scheme of the generation of induced pluripotent stem (IPS) cells. (1) Isolate and culture donor cells. (2) Transduce stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3) Harvest and culture the cells according to ES cell culture, using mitotically inactivated feeder cells (lightgray). (4) A small subset of the transfected cells become iPS cells and generate ES-like colonies.

iPSCs are typically derived by introducing products of specific sets of pluripotency-associated genes, or "reprogramming factors", into a given cell type. The original set of reprogramming factors (also dubbed Yamanaka factors) are the transcription factors Oct4 (Pou5f1), Sox2, Klf4 and cMyc. While this combination is most conventional in producing iPSCs, each of the factors can be functionally replaced by related transcription factors, miRNAs, small molecules, or even non-related genes such as lineage specifiers. [11] It is also clear that pro-mitotic factors such as C-MYC/L-MYC or repression of cell cycle checkpoints, such as p53, are conduits to creating a compliant cellular state for iPSC reprogramming. [12]

iPSC derivation is typically a slow and inefficient process, taking one–two weeks for mouse cells and three–four weeks for human cells, with efficiencies around 0.01–0.1%. However, considerable advances have been made in improving the efficiency and the time it takes to obtain iPSCs. Upon introduction of reprogramming factors, cells begin to form colonies that resemble pluripotent stem cells, which can be isolated based on their morphology, conditions that select for their growth, or through expression of surface markers or reporter genes.

First generation (mouse)

Induced pluripotent stem cells were first generated by Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University, Japan, in 2006. [1] They hypothesized that genes important to embryonic stem cell (ESC) function might be able to induce an embryonic state in adult cells. They chose twenty-four genes previously identified as important in ESCs and used retroviruses to deliver these genes to mouse fibroblasts. The fibroblasts were engineered so that any cells reactivating the ESC-specific gene, Fbx15, could be isolated using antibiotic selection.

Upon delivery of all twenty-four factors, ESC-like colonies emerged that reactivated the Fbx15 reporter and could propagate indefinitely. To identify the genes necessary for reprogramming, the researchers removed one factor at a time from the pool of twenty-four. By this process, they identified four factors, Oct4, Sox2, cMyc, and Klf4, which were each necessary and together sufficient to generate ESC-like colonies under selection for reactivation of Fbx15.

Second generation (mouse)

In June 2007, three separate research groups, including that of Yamanaka's, a Harvard/University of California, Los Angeles collaboration, and a group at MIT, published studies that substantially improved on the reprogramming approach, giving rise to iPSCs that were indistinguishable from ESCs. Unlike the first generation of iPSCs, these second generation iPSCs produced viable chimeric mice and contributed to the mouse germline, thereby achieving the 'gold standard' for pluripotent stem cells.

These second-generation iPSCs were derived from mouse fibroblasts by retroviral-mediated expression of the same four transcription factors (Oct4, Sox2, cMyc, Klf4). However, instead of using Fbx15 to select for pluripotent cells, the researchers used Nanog, a gene that is functionally important in ESCs. By using this different strategy, the researchers created iPSCs that were functionally identical to ESCs. [13] [14] [15] [16]

Human induced pluripotent stem cells

Generation from human fibroblasts

Reprogramming of human cells to iPSCs was reported in November 2007 by two independent research groups: Shinya Yamanaka of Kyoto University, Japan, who pioneered the original iPSC method, and James Thomson of University of Wisconsin-Madison who was the first to derive human embryonic stem cells. With the same principle used in mouse reprogramming, Yamanaka's group successfully transformed human fibroblasts into iPSCs with the same four pivotal genes, Oct4, Sox2, Klf4, and cMyc, using a retroviral system, [17] while Thomson and colleagues used a different set of factors, Oct4, Sox2, Nanog, and Lin28, using a lentiviral system. [18]

Generation from additional cell types

Obtaining fibroblasts to produce iPSCs involves a skin biopsy, and there has been a push towards identifying cell types that are more easily accessible. [19] [20] In 2008, iPSCs were derived from human keratinocytes, which could be obtained from a single hair pluck. [21] [22] In 2010, iPSCs were derived from peripheral blood cells, [23] [24] and in 2012, iPSCs were made from renal epithelial cells in the urine. [25]

Other considerations for starting cell type include mutational load (for example, skin cells may harbor more mutations due to UV exposure), [19] [20] time it takes to expand the population of starting cells, [19] and the ability to differentiate into a given cell type. [26]

Genes used to produce iPSCs

[ citation needed ]

The generation of induced pluripotent cells is crucially dependent on the transcription factors used for the induction.

Oct-3/4 and certain products of the Sox gene family (Sox1, Sox2, Sox3, and Sox15) have been identified as crucial transcriptional regulators involved in the induction process whose absence makes induction impossible. Additional genes, however, including certain members of the Klf family (Klf1, Klf2, Klf4, and Klf5), the Myc family (c-myc, L-myc, and N-myc), Nanog, and LIN28, have been identified to increase the induction efficiency.

Challenges in reprogramming cells to pluripotency

Although the methods pioneered by Yamanaka and others have demonstrated that adult cells can be reprogrammed to iPS cells, there are still challenges associated with this technology:

  1. Low efficiency: in general, the conversion to iPS cells has been incredibly low. For example, the rate at which somatic cells were reprogrammed into iPS cells in Yamanaka's original mouse study was 0.01–0.1%. [1] The low efficiency rate may reflect the need for precise timing, balance, and absolute levels of expression of the reprogramming genes. It may also suggest a need for rare genetic or epigenetic changes in the original somatic cell population or in the prolonged culture. However, recently a path was found for efficient reprogramming which required downregulation of the nucleosome remodeling and deacetylation (NuRD) complex. Overexpression of Mbd3, a subunit of NuRD, inhibits induction of iPSCs. Depletion of Mbd3, on the other hand, improves reprogramming efficiency, [32] that results in deterministic and synchronized iPS cell reprogramming (near 100% efficiency within seven days from mouse and human cells). [33]
  2. Genomic Insertion: genomic integration of the transcription factors limits the utility of the transcription factor approach because of the risk of mutations being inserted into the target cell's genome. [34] A common strategy for avoiding genomic insertion has been to use a different vector for input. Plasmids, adenoviruses, and transposon vectors have all been explored, but these often come with the tradeoff of lower throughput. [35] [36] [37]
  3. Tumorigenicity: Depending on the methods used, reprogramming of adult cells to obtain iPSCs may pose significant risks that could limit their use in humans. For example, if viruses are used to genomically alter the cells, the expression of oncogenes (cancer-causing genes) may potentially be triggered. In February 2008, scientists announced the discovery of a technique that could remove oncogenes after the induction of pluripotency, thereby increasing the potential use of iPS cells in human diseases. [38] In another study, Yamanaka reported that one can create iPSCs without the oncogene c-Myc. The process took longer and was not as efficient, but the resulting chimeras did not develop cancer. [39] Inactivation or deletion of the tumor suppressor p53, which is a key regulator of cancer, significantly increases reprogramming efficiency. [40] Thus there seems to be a tradeoff between reprogramming efficiency and tumor generation.
  4. Incomplete reprogramming: reprogramming also faces the challenge of completeness. This is particularly challenging because the genome-wide epigenetic code must be reformatted to that of the target cell type in order to fully reprogram a cell. However, three separate groups were able to find mouse embryonic fibroblast (MEF)-derived iPS cells that could be injected into tetraploid blastocysts and resulted in the live birth of mice derived entirely from iPS cells, thus ending the debate over the equivalence of embryonic stem cells (ESCs) and iPS with regard to pluripotency. [41]

The table on the right summarizes the key strategies and techniques used to develop iPS cells in the first five years after Yamanaka et al.'s 2006 breakthrough. Rows of similar colors represent studies that used similar strategies for reprogramming.

This timeline summarizes the key strategies and techniques used to develop iPS cells in the first five years after Yamanaka et al.'s 2006 breakthrough. Rows of similar colors represent studies that used similar strategies for reprogramming. Production of iPSC Timeline.png
This timeline summarizes the key strategies and techniques used to develop iPS cells in the first five years after Yamanaka et al.'s 2006 breakthrough. Rows of similar colors represent studies that used similar strategies for reprogramming.

Alternative approaches

Mimicking transcription factors with chemicals

One of the main strategies for avoiding problems (1) and (2) has been to use small molecules that can mimic the effects of transcription factors. These compounds can compensate for a reprogramming factor that does not effectively target the genome or fails at reprogramming for another reason; thus they raise reprogramming efficiency. They also avoid the problem of genomic integration, which in some cases contributes to tumor genesis. Key studies using such strategy were conducted in 2008. Melton et al. studied the effects of histone deacetylase (HDAC) inhibitor valproic acid. They found that it increased reprogramming efficiency 100-fold (compared to Yamanaka's traditional transcription factor method). [42] The researchers proposed that this compound was mimicking the signaling that is usually caused by the transcription factor c-Myc. A similar type of compensation mechanism was proposed to mimic the effects of Sox2. In 2008, Ding et al. used the inhibition of histone methyl transferase (HMT) with BIX-01294 in combination with the activation of calcium channels in the plasma membrane in order to increase reprogramming efficiency. [43] Deng et al. of Beijing University reported in July 2013 that induced pluripotent stem cells can be created without any genetic modification. They used a cocktail of seven small-molecule compounds including DZNep to induce the mouse somatic cells into stem cells which they called CiPS cells with the efficiency – at 0.2% – comparable to those using standard iPSC production techniques. The CiPS cells were introduced into developing mouse embryos and were found to contribute to all major cells types, proving its pluripotency. [44] [45]

Ding et al. demonstrated an alternative to transcription factor reprogramming through the use of drug-like chemicals. By studying the mesenchymal-epithelial transition (MET) process in which fibroblasts are pushed to a stem-cell like state, Ding's group identified two chemicals – ALK5 inhibitor SB431412 and MEK (mitogen-activated protein kinase) inhibitor PD0325901 – which was found to increase the efficiency of the classical genetic method by 100 fold. Adding a third compound known to be involved in the cell survival pathway, thiazovivin further increases the efficiency by 200 fold. Using the combination of these three compounds also decreased the reprogramming process of the human fibroblasts from four weeks to two weeks. [46] [47]

In April 2009, it was demonstrated that generation of iPS cells is possible without any genetic alteration of the adult cell: a repeated treatment of the cells with certain proteins channeled into the cells via poly-arginine anchors was sufficient to induce pluripotency. [48] The acronym given for those iPSCs is piPSCs (protein-induced pluripotent stem cells).

Alternate vectors

Another key strategy for avoiding problems such as tumorgenesis and low throughput has been to use alternate forms of vectors: adenoviruses, plasmids, and naked DNA or protein compounds.

In 2008, Hochedlinger et al. used an adenovirus to transport the requisite four transcription factors into the DNA of skin and liver cells of mice, resulting in cells identical to ESCs. The adenovirus is unique from other vectors like viruses and retroviruses because it does not incorporate any of its own genes into the targeted host and avoids the potential for insertional mutagenesis. [43] In 2009, Freed et al. demonstrated successful reprogramming of human fibroblasts to iPS cells. [49] Another advantage of using adenoviruses is that they only need to present for a brief amount of time in order for effective reprogramming to take place.

Also in 2008, Yamanaka et al. found that they could transfer the four necessary genes with a plasmid. [35] The Yamanaka group successfully reprogrammed mouse cells by transfection with two plasmid constructs carrying the reprogramming factors; the first plasmid expressed c-Myc, while the second expressed the other three factors (Oct4, Klf4, and Sox2). Although the plasmid methods avoid viruses, they still require cancer-promoting genes to accomplish reprogramming. The other main issue with these methods is that they tend to be much less efficient compared to retroviral methods. Furthermore, transfected plasmids have been shown to integrate into the host genome and therefore they still pose the risk of insertional mutagenesis. Because non-retroviral approaches have demonstrated such low efficiency levels, researchers have attempted to effectively rescue the technique with what is known as the PiggyBac Transposon System. Several studies have demonstrated that this system can effectively deliver the key reprogramming factors without leaving footprint mutations in the host cell genome. The PiggyBac Transposon System involves the re-excision of exogenous genes, which eliminates the issue of insertional mutagenesis.[ citation needed ]

Stimulus-triggered acquisition of pluripotency cell

In January 2014, two articles were published claiming that a type of pluripotent stem cell can be generated by subjecting the cells to certain types of stress (bacterial toxin, a low pH of 5.7, or physical squeezing); the resulting cells were called STAP cells, for stimulus-triggered acquisition of pluripotency. [50]

In light of difficulties that other labs had replicating the results of the surprising study, in March 2014, one of the co-authors has called for the articles to be retracted. [51] On 4 June 2014, the lead author, Obokata agreed to retract both the papers [52] after she was found to have committed 'research misconduct' as concluded in an investigation by RIKEN on 1 April 2014. [53]

RNA molecules

MicroRNAs are short RNA molecules that bind to complementary sequences on messenger RNA and block expression of a gene. Measuring variations in microRNA expression in iPS cells can be used to predict their differentiation potential. [54] Addition of microRNAs can also be used to enhance iPS potential. Several mechanisms have been proposed. [54] ES cell-specific microRNA molecules (such as miR-291, miR-294 and miR-295) enhance the efficiency of induced pluripotency by acting downstream of c-Myc. [55] MicroRNAs can also block expression of repressors of Yamanaka's four transcription factors, and there may be additional mechanisms induce reprogramming even in the absence of added exogenous transcription factors. [54]

Identity

Three germ line cells/tissues differentiated from iPSCs: neurons (ectoderm), cartilage (soft bone, mesoderm) and goblet cells in intestine (endoderm) Three germ line cells differentiated from iPSCs.png
Three germ line cells/tissues differentiated from iPSCs: neurons (ectoderm), cartilage (soft bone, mesoderm) and goblet cells in intestine (endoderm)

Induced pluripotent stem cells are similar to natural pluripotent stem cells, such as embryonic stem cells, in many aspects, such as the expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability, but the full extent of their relation to natural pluripotent stem cells is still being assessed. [1]

Gene expression and genome-wide H3K4me3 and H3K27me3 were found to be extremely similar between ES and iPS cells. [56] [ citation needed ] The generated iPSCs were remarkably similar to naturally isolated pluripotent stem cells (such as mouse and human embryonic stem cells, mESCs and hESCs, respectively) in the following respects, thus confirming the identity, authenticity, and pluripotency of iPSCs to naturally isolated pluripotent stem cells:

Safety

Medical research

The task of producing iPS cells continues to be challenging due to the six problems mentioned above. A key tradeoff to overcome is that between efficiency and genomic integration. Most methods that do not rely on the integration of transgenes are inefficient, while those that do rely on the integration of transgenes face the problems of incomplete reprogramming and tumor genesis, although a vast number of techniques and methods have been attempted. Another large set of strategies is to perform a proteomic characterization of iPS cells. [58] Further studies and new strategies should generate optimal solutions to the five main challenges. One approach might attempt to combine the positive attributes of these strategies into an ultimately effective technique for reprogramming cells to iPS cells.

Another approach is the use of iPS cells derived from patients to identify therapeutic drugs able to rescue a phenotype. For instance, iPS cell lines derived from patients affected by ectodermal dysplasia syndrome (EEC), in which the p63 gene is mutated, display abnormal epithelial commitment that could be partially rescued by a small compound. [67]

Disease modeling and drug development

An attractive feature of human iPS cells is the ability to derive them from adult patients to study the cellular basis of human disease. Since iPS cells are self-renewing and pluripotent, they represent a theoretically unlimited source of patient-derived cells which can be turned into any type of cell in the body. This is particularly important because many other types of human cells derived from patients tend to stop growing after a few passages in laboratory culture. iPS cells have been generated for a wide variety of human genetic diseases, including common disorders such as Down syndrome and polycystic kidney disease. [68] [69] [70] In many instances, the patient-derived iPS cells exhibit cellular defects not observed in iPS cells from healthy subjects, providing insight into the pathophysiology of the disease. [71] [72] An international collaborated project, StemBANCC, was formed in 2012 to build a collection of iPS cell lines for drug screening for a variety of diseases. Managed by the University of Oxford, the effort pooled funds and resources from 10 pharmaceutical companies and 23 universities. The goal is to generate a library of 1,500 iPS cell lines which will be used in early drug testing by providing a simulated human disease environment. [73] Furthermore, combining hiPSC technology and small molecule or genetically encoded voltage and calcium indicators provided a large-scale and high-throughput platform for cardiovascular drug safety screening. [74] [75] [76] [77] [78]

Organ synthesis

A proof-of-concept of using induced pluripotent stem cells (iPSCs) to generate human organ for transplantation was reported by researchers from Japan. Human 'liver buds' (iPSC-LBs) were grown from a mixture of three different kinds of stem cells: hepatocyte (for liver function) coaxed from iPSCs; endothelial stem cells (to form lining of blood vessels) from umbilical cord blood; and mesenchymal stem cells (to form connective tissue). This new approach allows different cell types to self-organize into a complex organ, mimicking the process in fetal development. After growing in vitro for a few days, the liver buds were transplanted into mice where the 'liver' quickly connected with the host blood vessels and continued to grow. Most importantly, it performed regular liver functions including metabolizing drugs and producing liver-specific proteins. Further studies will monitor the longevity of the transplanted organ in the host body (ability to integrate or avoid rejection) and whether it will transform into tumors. [79] [80]

Organ regeneration

In 2021, a switchable Yamanaka factors-reprogramming-based approach for regeneration of damaged heart without tumor-formation was demonstrated in mice and was successful if the intervention was carried out immediately before or after a heart attack. [81]

Tissue repair

Embryonic cord-blood cells were induced into pluripotent stem cells using plasmid DNA. Using cell surface endothelial/pericytic markers CD31 and CD146, researchers identified 'vascular progenitor', the high-quality, multipotent vascular stem cells. After the iPS cells were injected directly into the vitreous of the damaged retina of mice, the stem cells engrafted into the retina, grew and repaired the vascular vessels. [82] [83]

Labelled iPSCs-derived NSCs injected into laboratory animals with brain lesions were shown to migrate to the lesions and some motor function improvement was observed. [84]

Cardiomyocytes

Beating cardiac muscle cells, iPSC-derived cardiomyocytes, can be mass-produced using chemically defined differentiation protocols. [85] [86] These protocols typically modulate the same developmental signaling pathways required for heart development. [87] These iPSC-cardiomyocytes can recapitulate genetic arrhythmias and cardiac drug responses, since they exhibit the same genetic background as the patient from which they were derived. [88] [89] [90] [91]

In June 2014, Takara Bio received technology transfer from iHeart Japan, a venture company from Kyoto University's iPS Cell Research Institute, to make it possible to exclusively use technologies and patents that induce differentiation of iPS cells into cardiomyocytes in Asia. The company announced the idea of selling cardiomyocytes to pharmaceutical companies and universities to help develop new drugs for heart disease. [92]

On March 9, 2018, the Specified Regenerative Medicine Committee of Osaka University officially approved the world's first clinical research plan to transplant a "myocardial sheet" made from iPS cells into the heart of patients with severe heart failure. Osaka University announced that it had filed an application with the Ministry of Health, Labor and Welfare on the same day.

On May 16, 2018, the clinical research plan was approved by the Ministry of Health, Labor and Welfare's expert group with a condition. [93] [94]

In October 2019, a group at Okayama University developed a model of ischemic heart disease using cardiomyocytes differentiated from iPS cells. [95]

Red blood cells

Although a pint of donated blood contains about two trillion red blood cells and over 107 million blood donations are collected globally, there is still a critical need for blood for transfusion. In 2014, type O red blood cells were synthesized at the Scottish National Blood Transfusion Service from iPSC. The cells were induced to become a mesoderm and then blood cells and then red blood cells. The final step was to make them eject their nuclei and mature properly. Type O can be transfused into all patients. Human clinical trials were not expected to begin before 2016. [96]

Clinical trial

The first human clinical trial using autologous iPSCs was approved by the Japan Ministry Health and was to be conducted in 2014 at the Riken Center for Developmental Biology in Kobe. However the trial was suspended after Japan's new regenerative medicine laws came into effect in November 2015. [97] More specifically, an existing set of guidelines was strengthened to have the force of law (previously mere recommendations). [98] iPSCs derived from skin cells from six patients with wet age-related macular degeneration were reprogrammed to differentiate into retinal pigment epithelial (RPE) cells. The cell sheet would be transplanted into the affected retina where the degenerated RPE tissue was excised. Safety and vision restoration monitoring were to last one to three years. [99] [100]

In March 2017, a team led by Masayo Takahashi completed the first successful transplant of iPS-derived retinal cells from a donor into the eye of a person with advanced macular degeneration. [101] However it was reported that they are now having complications. [102] The benefits of using autologous iPSCs are that there is theoretically no risk of rejection and that it eliminates the need to use embryonic stem cells. However, these iPSCs were derived from another person. [100]

New clinical trials involving iPSCs are now ongoing not only in Japan, but also in the US and Europe. [103] Research in 2021 on the trial registry Clinicaltrials.gov identified 129 trial listings mentioning iPSCs, but most were non-interventional. [104]

Strategy for obtaining universal iPSCs

To make iPSC-based regenerative medicine technologies available to more patients, it is necessary to create universal iPSCs that can be transplanted independently of haplotypes of HLA. The current strategy for the creation of universal iPSCs has two main goals: to remove HLA expression and to prevent NK cells attacks due to deletion of HLA. Deletion of the B2M and CIITA genes using the CRISPR/Cas9 system has been reported to suppress the expression of HLA class I and class II, respectively. To avoid NK cell attacks. transduction of ligands inhibiting NK-cells, such as HLA-E and CD47 has been used. [105] HLA-C is left unchanged, since the 12 common HLA-C alleles are enough to cover 95% of the world's population. [105]

Anti-aging properties

A multipotent mesenchymal stem cell, when induced into pluripotence, holds great promise to slow or reverse aging phenotypes. Such anti-aging properties were demonstrated in early clinical trials in 2017. [106] In 2020, Stanford University researchers concluded after studying elderly mice that old human cells when subjected to the Yamanaka factors, might rejuvenate and become nearly indistinguishable from their younger counterparts. [107]

See also

Related Research Articles

<span class="mw-page-title-main">Stem cell</span> Undifferentiated biological cells that can differentiate into specialized cells

In multicellular organisms, stem cells are undifferentiated or partially differentiated cells that can change into various types of cells and proliferate indefinitely to produce more of the same stem cell. They are the earliest type of cell in a cell lineage. They are found in both embryonic and adult organisms, but they have slightly different properties in each. They are usually distinguished from progenitor cells, which cannot divide indefinitely, and precursor or blast cells, which are usually committed to differentiating into one cell type.

Transdifferentiation, also known as lineage reprogramming, is the process in which one mature somatic cell is transformed into another mature somatic cell without undergoing an intermediate pluripotent state or progenitor cell type. It is a type of metaplasia, which includes all cell fate switches, including the interconversion of stem cells. Current uses of transdifferentiation include disease modeling and drug discovery and in the future may include gene therapy and regenerative medicine. The term 'transdifferentiation' was originally coined by Selman and Kafatos in 1974 to describe a change in cell properties as cuticle producing cells became salt-secreting cells in silk moths undergoing metamorphosis.

<span class="mw-page-title-main">Cellular differentiation</span> Transformation of a stem cell to a more specialized cell

Cellular differentiation is the process in which a stem cell changes from one type to a differentiated one. Usually, the cell changes to a more specialized type. Differentiation happens multiple times during the development of a multicellular organism as it changes from a simple zygote to a complex system of tissues and cell types. Differentiation continues in adulthood as adult stem cells divide and create fully differentiated daughter cells during tissue repair and during normal cell turnover. Some differentiation occurs in response to antigen exposure. Differentiation dramatically changes a cell's size, shape, membrane potential, metabolic activity, and responsiveness to signals. These changes are largely due to highly controlled modifications in gene expression and are the study of epigenetics. With a few exceptions, cellular differentiation almost never involves a change in the DNA sequence itself. Metabolic composition, however, gets dramatically altered where stem cells are characterized by abundant metabolites with highly unsaturated structures whose levels decrease upon differentiation. Thus, different cells can have very different physical characteristics despite having the same genome.

<span class="mw-page-title-main">Somatic cell nuclear transfer</span> Method of creating a cloned embryo by replacing the egg nucleus with a body cell nucleus

In genetics and developmental biology, somatic cell nuclear transfer (SCNT) is a laboratory strategy for creating a viable embryo from a body cell and an egg cell. The technique consists of taking a denucleated oocyte and implanting a donor nucleus from a somatic (body) cell. It is used in both therapeutic and reproductive cloning. In 1996, Dolly the sheep became famous for being the first successful case of the reproductive cloning of a mammal. In January 2018, a team of scientists in Shanghai announced the successful cloning of two female crab-eating macaques from foetal nuclei.

<span class="mw-page-title-main">Embryonic stem cell</span> Type of pluripotent blastocystic stem cell

Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the inner cell mass (embryoblast) using immunosurgery results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage have the same moral considerations as embryos in the post-implantation stage of development.

<span class="mw-page-title-main">Oct-4</span> Mammalian protein found in Homo sapiens

Oct-4, also known as POU5F1, is a protein that in humans is encoded by the POU5F1 gene. Oct-4 is a homeodomain transcription factor of the POU family. It is critically involved in the self-renewal of undifferentiated embryonic stem cells. As such, it is frequently used as a marker for undifferentiated cells. Oct-4 expression must be closely regulated; too much or too little will cause differentiation of the cells.

<span class="mw-page-title-main">Homeobox protein NANOG</span> Mammalian protein found in humans

Homeobox protein NANOG(hNanog) is a transcriptional factor that helps embryonic stem cells (ESCs) maintain pluripotency by suppressing cell determination factors. hNanog is encoded in humans by the NANOG gene. Several types of cancer are associated with NANOG.

In biology, reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA methylation, during mammalian development or in cell culture. Such control is also often associated with alternative covalent modifications of histones.

In biology and medicine, stem cell genomics is the analysis of the genomes of stem cells. Currently, this field is rapidly expanding due to the dramatic decrease in the cost of sequencing genomes. The study of stem cell genomics has wide reaching implications in the study of stem cell biology and possible therapeutic usages of stem cells.

<span class="mw-page-title-main">Telomerase reverse transcriptase</span> Catalytic subunit of the enzyme telomerase

Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase, which, together with the telomerase RNA component (TERC), comprises the most important unit of the telomerase complex.

<span class="mw-page-title-main">KLF4</span> Protein-coding gene in the species Homo sapiens

Krüppel-like factor 4 is a member of the KLF family of zinc finger transcription factors, which belongs to the relatively large family of SP1-like transcription factors. KLF4 is involved in the regulation of proliferation, differentiation, apoptosis and somatic cell reprogramming. Evidence also suggests that KLF4 is a tumor suppressor in certain cancers, including colorectal cancer. It has three C2H2-zinc fingers at its carboxyl terminus that are closely related to another KLF, KLF2. It has two nuclear localization sequences that signals it to localize to the nucleus. In embryonic stem cells (ESCs), KLF4 has been demonstrated to be a good indicator of stem-like capacity. It is suggested that the same is true in mesenchymal stem cells (MSCs).

<span class="mw-page-title-main">SOX2</span> Transcription factor gene of the SOX family

SRY -box 2, also known as SOX2, is a transcription factor that is essential for maintaining self-renewal, or pluripotency, of undifferentiated embryonic stem cells. Sox2 has a critical role in maintenance of embryonic and neural stem cells.

<span class="mw-page-title-main">Shinya Yamanaka</span> Japanese stem cell researcher (born 1962)

Shinya Yamanaka is a Japanese stem cell researcher and a Nobel Prize laureate. He is a professor and the director emeritus of Center for iPS Cell Research and Application, Kyoto University; as a senior investigator at the UCSF-affiliated Gladstone Institutes in San Francisco, California; and as a professor of anatomy at University of California, San Francisco (UCSF). Yamanaka is also a past president of the International Society for Stem Cell Research (ISSCR).

A mesenchymal–epithelial transition (MET) is a reversible biological process that involves the transition from motile, multipolar or spindle-shaped mesenchymal cells to planar arrays of polarized cells called epithelia. MET is the reverse process of epithelial–mesenchymal transition (EMT) and it has been shown to occur in normal development, induced pluripotent stem cell reprogramming, cancer metastasis and wound healing.

<span class="mw-page-title-main">Cell potency</span> Ability of a cell to differentiate into other cell types

Cell potency is a cell's ability to differentiate into other cell types. The more cell types a cell can differentiate into, the greater its potency. Potency is also described as the gene activation potential within a cell, which like a continuum, begins with totipotency to designate a cell with the most differentiation potential, pluripotency, multipotency, oligopotency, and finally unipotency.

<span class="mw-page-title-main">GLIS1</span> Protein-coding gene

Glis1 is gene encoding a Krüppel-like protein of the same name whose locus is found on Chromosome 1p32.3. The gene is enriched in unfertilised eggs and embryos at the one cell stage and it can be used to promote direct reprogramming of somatic cells to induced pluripotent stem cells, also known as iPS cells. Glis1 is a highly promiscuous transcription factor, regulating the expression of numerous genes, either positively or negatively. In organisms, Glis1 does not appear to have any directly important functions. Mice whose Glis1 gene has been removed have no noticeable change to their phenotype.

Directed differentiation is a bioengineering methodology at the interface of stem cell biology, developmental biology and tissue engineering. It is essentially harnessing the potential of stem cells by constraining their differentiation in vitro toward a specific cell type or tissue of interest. Stem cells are by definition pluripotent, able to differentiate into several cell types such as neurons, cardiomyocytes, hepatocytes, etc. Efficient directed differentiation requires a detailed understanding of the lineage and cell fate decision, often provided by developmental biology.

After the blastocyst stage, once an embryo implanted in endometrium, the inner cell mass (ICM) of a fertilized embryo segregates into two layers: hypoblast and epiblast. The epiblast cells are the functional progenitors of soma and germ cells which later differentiate into three layers: definitive endoderm, mesoderm and ectoderm. Stem cells derived from epiblast are pluripotent. These cells are called epiblast-derived stem cells (EpiSCs) and have several different cellular and molecular characteristics with Embryonic Stem Cells (ESCs). Pluripotency in EpiSCs is essentially different from that of embryonic stem cells. The pluripotency of EpiSCs is primed pluripotency: primed to differentiate into specific cell lineages. Naïve pluripotent stem cells and primed pluripotent stem cells not only sustain the ability to self-renew but also maintain the capacity to differentiate. Since the cell status is primed to differentiate in EpiSCs, however, one copy of the X chromosome in XX cells in EpiSCs is silenced (XaXi). EpiSCs is unable to colonize and is not available to be used to produce chimeras. Conversely, XX cells in ESCs are both active and can produce chimera when inserted into a blastocyst. Both ESC and EpiSC induce teratoma when injected in the test animals which proves pluripotency. EpiSC display several distinctive characteristics distinct from ESCs. The cellular status of human ESCs (hESCs) is similar to primed state mouse stem cells rather than naïve state.

<span class="mw-page-title-main">F-box protein 15</span>

F-box protein 15 also known as Fbx15 is a protein that in humans is encoded by the FBXO15 gene.

Transflammation describes the process by which innate immune response mechanisms affect the epigenetic plasticity of a cell during nuclear reprogramming. This phenomenon is essential in dedifferentiating a somatic cell to a pluripotent cell and also in transdifferentiating a terminally differentiated cell to another terminally differentiated cell.

References

  1. 1 2 3 4 Takahashi K, Yamanaka S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell. 126 (4): 663–76. doi: 10.1016/j.cell.2006.07.024 . hdl: 2433/159777 . PMID   16904174. Open Access logo PLoS transparent.svg
  2. ↑ "The Nobel Prize in Physiology or Medicine – 2012 Press Release". Nobel Media AB. 8 October 2012.
  3. ↑ Mahla RS (2016). "Stem Cells Applications in Regenerative Medicine and Disease Therapeutics". International Journal of Cell Biology. 2016: 6940283. doi: 10.1155/2016/6940283 . PMC   4969512 . PMID   27516776.
  4. ↑ Klimanskaya I, Chung Y, Becker S, Lu SJ, Lanza R (November 2006). "Human embryonic stem cell lines derived from single blastomeres". Nature. 444 (7118): 481–5. Bibcode:2006Natur.444..481K. doi:10.1038/nature05142. PMID   16929302. S2CID   84792371.
  5. ↑ Hockemeyer D, Jaenisch R (May 2016). "Induced Pluripotent Stem Cells Meet Genome Editing". Cell Stem Cell. 18 (5): 573–86. doi:10.1016/j.stem.2016.04.013. PMC   4871596 . PMID   27152442.
  6. ↑ "「i」PSなぜ小文字？ 山中さんってどんな人？". 朝日新聞. 8 October 2012. Archived from the original on 21 November 2012. Retrieved 27 April 2013.
  7. ↑ "万能なiPS細胞「iPodのように普及してほしい」". スポーツニッポン. 9 October 2012. Retrieved 14 October 2012.
  8. ↑ "山中教授の「iPS細胞」ってiPod のパクリ!?流行らせたいと頭小文字". J-CASTニュース. 9 October 2012. Retrieved 28 April 2013.
  9. ↑ Eguizabal C, Aran B, Chuva de Sousa Lopes SM, Geens M, Heindryckx B, Panula S, Popovic M, Vassena R, Veiga A (2019). "Two decades of embryonic stem cells: a historical overview". Human Reproduction Open. 2019 (1): hoy024. doi: 10.1093/hropen/hoy024 . PMC   6396646 . PMID   30895264.
  10. ↑ Yamanaka S (December 2013). "The winding road to pluripotency (Nobel Lecture)". Angewandte Chemie. 52 (52): 13900–9. doi:10.1002/anie.201306721. PMID   24255017.
  11. ↑ Guo XL, Chen JS (2015). "Research on induced pluripotent stem cells and the application in ocular tissues". International Journal of Ophthalmology. 8 (4): 818–25. doi:10.3980/j.issn.2222-3959.2015.04.31. PMC   4539634 . PMID   26309885.
  12. ↑ Thornton, Christopher D.; Fielding, Stuart; Karbowniczek, Kinga; Roig-Merino, Alicia; Burrows, Alysha E.; FitzPatrick, Lorna M.; Sharaireh, Aseel; Tite, John P.; Mole, Sara E.; Harbottle, Richard P.; Caproni, Lisa J.; McKay, Tristan R. (10 December 2021). "Safe and stable generation of induced pluripotent stem cells using doggybone DNA vectors". Molecular Therapy - Methods & Clinical Development. 23: 348–358. doi:10.1016/j.omtm.2021.09.018. ISSN   2329-0501. PMC   8546411 . PMID   34729381.
  13. ↑ Okita K, Ichisaka T, Yamanaka S (July 2007). "Generation of germline-competent induced pluripotent stem cells". Nature. 448 (7151): 313–7. Bibcode:2007Natur.448..313O. doi:10.1038/nature05934. PMID   17554338. S2CID   459050.
  14. ↑ Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. (July 2007). "In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state". Nature. 448 (7151): 318–24. Bibcode:2007Natur.448..318W. doi:10.1038/nature05944. PMID   17554336. S2CID   4377572.
  15. ↑ Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, et al. (June 2007). "Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution". Cell Stem Cell. 1 (1): 55–70. doi: 10.1016/j.stem.2007.05.014 . PMID   18371336.
  16. ↑ "Generations of iPSCs and related references". Archived from the original on 30 June 2018. Retrieved 5 November 2007.
  17. ↑ Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–72. doi: 10.1016/j.cell.2007.11.019 . hdl: 2433/49782 . PMID   18035408.
  18. 1 2 Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. (December 2007). "Induced pluripotent stem cell lines derived from human somatic cells". Science. 318 (5858): 1917–20. Bibcode:2007Sci...318.1917Y. doi:10.1126/science.1151526. PMID   18029452. S2CID   86129154.
  19. 1 2 3 Yamanaka S (July 2010). "Patient-specific pluripotent stem cells become even more accessible". Cell Stem Cell. 7 (1): 1–2. doi: 10.1016/j.stem.2010.06.009 . PMID   20621038.
  20. 1 2 Maherali N, Hochedlinger K (December 2008). "Guidelines and techniques for the generation of induced pluripotent stem cells". Cell Stem Cell. 3 (6): 595–605. doi: 10.1016/j.stem.2008.11.008 . PMID   19041776.
  21. ↑ Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K (September 2008). "A high-efficiency system for the generation and study of human induced pluripotent stem cells". Cell Stem Cell. 3 (3): 340–5. doi:10.1016/j.stem.2008.08.003. PMC   3987901 . PMID   18786420.
  22. ↑ Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. (November 2008). "Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes". Nature Biotechnology. 26 (11): 1276–84. doi:10.1038/nbt.1503. PMID   18931654. S2CID   205274019.
  23. ↑ Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, et al. (July 2010). "Reprogramming of human peripheral blood cells to induced pluripotent stem cells". Cell Stem Cell. 7 (1): 20–4. doi:10.1016/j.stem.2010.06.002. PMC   2917234 . PMID   20621045.
  24. ↑ Loh YH, Hartung O, Li H, Guo C, Sahalie JM, Manos PD, et al. (July 2010). "Reprogramming of T cells from human peripheral blood". Cell Stem Cell. 7 (1): 15–9. doi:10.1016/j.stem.2010.06.004. PMC   2913590 . PMID   20621044.
  25. ↑ Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, et al. (December 2012). "Generation of human induced pluripotent stem cells from urine samples". Nature Protocols. 7 (12): 2080–9. doi:10.1038/nprot.2012.115. PMID   23138349. S2CID   205465442.
  26. ↑ Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, et al. (August 2010). "Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells". Nature Biotechnology. 28 (8): 848–55. doi:10.1038/nbt.1667. PMC   3148605 . PMID   20644536.
  27. ↑ Velychko S, Adachi K, Kim KP, Hou Y, MacCarthy CM, Wu G, Schöler HR (December 2019). "Excluding Oct4 from Yamanaka Cocktail Unleashes the Developmental Potential of iPSCs". Cell Stem Cell. 25 (6): 737–753.e4. doi:10.1016/j.stem.2019.10.002. PMC   6900749 . PMID   31708402.
  28. ↑ Quality of induced pluripotent stem cells is dramatically enhanced by omitting what was thought to be the most crucial reprogramming factor Oct4 is not only unnecessary but damaging during generation of mouse induced pluripotent stem cells (iPSCs)
  29. 1 2 3 MacCarthy, Caitlin M.; Wu, Guangming; Malik, Vikas; Menuchin-Lasowski, Yotam; Velychko, Taras; Keshet, Gal; Fan, Rui; Bedzhov, Ivan; Church, George M.; Jauch, Ralf; Cojocaru, Vlad; Schöler, Hans R.; Velychko, Sergiy (December 2023). "Highly cooperative chimeric super-SOX induces naive pluripotency across species". Cell Stem Cell. 31 (1): 127–147.e9. doi: 10.1016/j.stem.2023.11.010 . PMID   38141611.
  30. ↑ Ali PS, Ghoshdastider U, Hoffmann J, Brutschy B, Filipek S (November 2012). "Recognition of the let-7g miRNA precursor by human Lin28B". FEBS Letters. 586 (22): 3986–90. Bibcode:2012FEBSL.586.3986S. doi: 10.1016/j.febslet.2012.09.034 . PMID   23063642. S2CID   28899778.
  31. ↑ Maekawa M, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, Ichisaka T, et al. (June 2011). "Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1". Nature. 474 (7350): 225–9. doi:10.1038/nature10106. hdl: 2433/141930 . PMID   21654807. S2CID   4428172.
  32. ↑ Luo M, Ling T, Xie W, Sun H, Zhou Y, Zhu Q, et al. (July 2013). "NuRD blocks reprogramming of mouse somatic cells into pluripotent stem cells". Stem Cells. 31 (7): 1278–86. doi:10.1002/stem.1374. hdl: 10397/18487 . PMID   23533168. S2CID   206512562.
  33. ↑ Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S, et al. (October 2013). "Deterministic direct reprogramming of somatic cells to pluripotency". Nature. 502 (7469): 65–70. Bibcode:2013Natur.502...65R. doi:10.1038/nature12587. PMID   24048479. S2CID   4386833.
  34. ↑ Selvaraj V, Plane JM, Williams AJ, Deng W (April 2010). "Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies". Trends in Biotechnology. 28 (4): 214–23. doi:10.1016/j.tibtech.2010.01.002. PMC   2843790 . PMID   20149468.
  35. 1 2 Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S (November 2008). "Generation of mouse induced pluripotent stem cells without viral vectors". Science. 322 (5903): 949–53. Bibcode:2008Sci...322..949O. doi: 10.1126/science.1164270 . PMID   18845712. S2CID   23735743.
  36. ↑ Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K (November 2008). "Induced pluripotent stem cells generated without viral integration". Science. 322 (5903): 945–9. Bibcode:2008Sci...322..945S. doi:10.1126/science.1162494. PMC   3987909 . PMID   18818365.
  37. ↑ Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, et al. (April 2009). "piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells". Nature. 458 (7239): 766–70. Bibcode:2009Natur.458..766W. doi:10.1038/nature07863. PMC   3758996 . PMID   19252478.
  38. ↑ Kaplan K (6 March 2009). "Cancer threat removed from stem cells, scientists say". Los Angeles Times.
  39. ↑ Swaminathan N (30 November 2007). "Stem Cells – This Time Without the Cancer". Scientific American News. Retrieved 11 December 2007.
  40. ↑ Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. (August 2009). "A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity". Nature. 460 (7259): 1149–53. Bibcode:2009Natur.460.1149M. doi:10.1038/nature08287. PMC   3624089 . PMID   19668189.
  41. 1 2 Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. (September 2009). "iPS cells produce viable mice through tetraploid complementation". Nature. 461 (7260): 86–90. Bibcode:2009Natur.461...86Z. doi:10.1038/nature08267. PMID   19672241. S2CID   205217762.
  42. ↑ Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (July 2008). "Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds". Nature Biotechnology. 26 (7): 795–7. doi:10.1038/nbt1418. PMC   6334647 . PMID   18568017.
  43. 1 2 Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S (November 2008). "Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds". Cell Stem Cell. 3 (5): 568–74. doi: 10.1016/j.stem.2008.10.004 . PMID   18983970.
  44. ↑ Cyranoski D (18 July 2013). "Stem cells reprogrammed using chemicals alone". Nature News. doi:10.1038/nature.2013.13416. S2CID   88247014 . Retrieved 22 July 2013.
  45. ↑ Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. (August 2013). "Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds". Science. 341 (6146): 651–4. Bibcode:2013Sci...341..651H. doi:10.1126/science.1239278. PMID   23868920. S2CID   45685692.
  46. ↑ "Major Step In Making Better Stem Cells From Adult Tissue". Science Daily. 19 October 2009. Retrieved 30 September 2013.
  47. ↑ Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, et al. (November 2009). "A chemical platform for improved induction of human iPSCs". Nature Methods. 6 (11): 805–8. doi:10.1038/nmeth.1393. PMC   3724527 . PMID   19838168.
  48. 1 2 Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. (May 2009). "Generation of induced pluripotent stem cells using recombinant proteins". Cell Stem Cell. 4 (5): 381–4. doi: 10.1016/j.stem.2009.04.005 . PMC   10182564 . PMID   19398399.
  49. ↑ Zhou W, Freed CR (November 2009). "Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells". Stem Cells. 27 (11): 2667–74. doi: 10.1002/stem.201 . PMID   19697349. S2CID   41418742.
  50. ↑ David Cyranoski for Nature News. January 29, 2014 Acid bath offers easy path to stem cells
  51. ↑ Tracy Vence for the Scientist. March 11, 2014 Call for STAP Retractions
  52. ↑ Lies E (4 June 2014). "Japan researcher agrees to withdraw disputed stem cell paper". Reuters. Retrieved 4 June 2014.
  53. ↑ Press Release (1 April 2014). "Report on STAP Cell Research Paper Investigation". RIKEN. Retrieved 2 June 2014.
  54. 1 2 3 Bao X, Zhu X, Liao B, Benda C, Zhuang Q, Pei D, et al. (April 2013). "MicroRNAs in somatic cell reprogramming". Current Opinion in Cell Biology. 25 (2): 208–14. doi:10.1016/j.ceb.2012.12.004. PMID   23332905.
  55. ↑ Judson RL, Babiarz JE, Venere M, Blelloch R (May 2009). "Embryonic stem cell-specific microRNAs promote induced pluripotency". Nature Biotechnology. 27 (5): 459–61. doi:10.1038/nbt.1535. PMC   2743930 . PMID   19363475.
  56. ↑ Guenther MG, Frampton GM, Soldner F, Hockemeyer D, Mitalipova M, Jaenisch R, Young RA (August 2010). "Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells". Cell Stem Cell. 7 (2): 249–57. doi:10.1016/j.stem.2010.06.015. PMC   3010384 . PMID   20682450.
  57. ↑ Kang L, Wang J, Zhang Y, Kou Z, Gao S (August 2009). "iPS cells can support full-term development of tetraploid blastocyst-complemented embryos". Cell Stem Cell. 5 (2): 135–8. doi: 10.1016/j.stem.2009.07.001 . PMID   19631602.
  58. 1 2 Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. (September 2009). "Adult mice generated from induced pluripotent stem cells". Nature. 461 (7260): 91–4. Bibcode:2009Natur.461...91B. doi:10.1038/nature08310. PMID   19672243. S2CID   4423755.
  59. ↑ Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. (March 2011). "Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells". Nature. 471 (7336): 68–73. Bibcode:2011Natur.471...68L. doi:10.1038/nature09798. PMC   3100360 . PMID   21289626.
  60. ↑ Knoepfler PS (May 2009). "Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine". Stem Cells. 27 (5): 1050–6. doi:10.1002/stem.37. PMC   2733374 . PMID   19415771.
  61. ↑ Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, et al. (October 2011). "Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice". Proceedings of the National Academy of Sciences of the United States of America. 108 (40): 16825–30. Bibcode:2011PNAS..10816825N. doi: 10.1073/pnas.1108077108 . PMC   3189018 . PMID   21949375.
  62. ↑ Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, et al. (March 2015). "Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition". Stem Cell Reports. 4 (3): 360–73. doi:10.1016/j.stemcr.2015.01.006. PMC   4375796 . PMID   25684226.
  63. ↑ Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, et al. (August 2008). "Generation of pluripotent stem cells from adult mouse liver and stomach cells". Science. 321 (5889): 699–702. Bibcode:2008Sci...321..699A. doi:10.1126/science.1154884. hdl: 2433/124215 . PMID   18276851. S2CID   52869734.
  64. ↑ Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, Mácia A, et al. (September 2010). "Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection". Stem Cells. 28 (9): 1568–70. doi:10.1002/stem.471. PMC   2996086 . PMID   20641038.
  65. ↑ Zhao T, Zhang ZN, Rong Z, Xu Y (May 2011). "Immunogenicity of induced pluripotent stem cells". Nature. 474 (7350): 212–5. CiteSeerX   10.1.1.864.8029 . doi:10.1038/nature10135. PMID   21572395. S2CID   4416964.
  66. ↑ Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, et al. (February 2013). "Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells". Nature. 494 (7435): 100–4. Bibcode:2013Natur.494..100A. doi:10.1038/nature11807. PMID   23302801. S2CID   205232231.
  67. ↑ Shalom-Feuerstein R, Serror L, Aberdam E, Müller FJ, van Bokhoven H, Wiman KG, et al. (February 2013). "Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET". Proceedings of the National Academy of Sciences of the United States of America. 110 (6): 2152–6. Bibcode:2013PNAS..110.2152S. doi: 10.1073/pnas.1201753109 . PMC   3568301 . PMID   23355677.
  68. ↑ Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. (September 2008). "Disease-specific induced pluripotent stem cells". Cell. 134 (5): 877–86. doi:10.1016/j.cell.2008.07.041. PMC   2633781 . PMID   18691744.
  69. ↑ Freedman BS, Lam AQ, Sundsbak JL, Iatrino R, Su X, Koon SJ, et al. (October 2013). "Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations". Journal of the American Society of Nephrology. 24 (10): 1571–86. doi:10.1681/ASN.2012111089. PMC   3785271 . PMID   24009235.
  70. ↑ Dolmetsch R, Geschwind D (June 2011). "The human brain in a dish: the promise of iPSC-derived neurons". Cell. 145 (6): 831–4. doi: 10.1016/j.cell.2011.05.034 . PMC   3691069 . PMID   21663789.
  71. ↑ Grskovic M, Javaherian A, Strulovici B, Daley GQ (November 2011). "Induced pluripotent stem cells--opportunities for disease modeling and drug discovery". Nature Reviews. Drug Discovery. 10 (12): 915–29. doi:10.1038/nrd3577. PMID   22076509. S2CID   7945956.
  72. ↑ Shi Y, Inoue H, Wu JC, Yamanaka S (February 2017). "Induced pluripotent stem cell technology: a decade of progress". Nat Rev Drug Discov. 16 (2): 115–30. doi:10.1038/nrd.2016.245. PMC   6416143 . PMID   27980341.
  73. ↑ Gerlin A (5 December 2012). "Roche, Pfizer, Sanofi Plan $72.7 Million Stem-Cell Bank". Bloomberg.com. Retrieved 23 December 2012.
  74. ↑ Shinnawi R, Huber I, Maizels L, Shaheen N, Gepstein A, Arbel G, et al. (October 2015). "Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters". Stem Cell Reports. 5 (4): 582–96. doi:10.1016/j.stemcr.2015.08.009. PMC   4624957 . PMID   26372632.
  75. ↑ Shaheen N, Shiti A, Huber I, Shinnawi R, Arbel G, Gepstein A, et al. (June 2018). "Human Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets Expressing Genetically Encoded Voltage Indicator for Pharmacological and Arrhythmia Studies". Stem Cell Reports. 10 (6): 1879–1894. doi:10.1016/j.stemcr.2018.04.006. PMC   5989818 . PMID   29754959.
  76. ↑ Sharma, Arun; Burridge, Paul W.; McKeithan, Wesley L.; Serrano, Ricardo; Shukla, Praveen; Sayed, Nazish; Churko, Jared M.; Kitani, Tomoya; Wu, Haodi; Holmström, Alexandra; Matsa, Elena (15 February 2017). "High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells". Science Translational Medicine. 9 (377): eaaf2584. doi:10.1126/scitranslmed.aaf2584. ISSN   1946-6242. PMC   5409837 . PMID   28202772.
  77. ↑ McKeithan, Wesley L.; Savchenko, Alex; Yu, Michael S.; Cerignoli, Fabio; Bruyneel, Arne A. N.; Price, Jeffery H.; Colas, Alexandre R.; Miller, Evan W.; Cashman, John R.; Mercola, Mark (2017). "An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes". Frontiers in Physiology. 8: 766. doi: 10.3389/fphys.2017.00766 . ISSN   1664-042X. PMC   5641590 . PMID   29075196.
  78. ↑ Serrano, Ricardo; Feyen, Dries A.M.; Bruyneel, Arne A.N.; Hnatiuk, Anna P.; Vu, Michelle M.; Amatya, Prashila L.; Perea-Gil, Isaac; Prado, Maricela; Seeger, Timon; Wu, Joseph C.; Karakikes, Ioannis; Mercola, Mark (January 2023). "A deep learning platform to assess drug proarrhythmia risk". Cell Stem Cell. 30 (1): 86–95.e4. doi:10.1016/j.stem.2022.12.002. PMC   9924077 . PMID   36563695.
  79. ↑ Baker M (3 July 2013). "Miniature human liver grown in mice". Nature. doi:10.1038/nature.2013.13324. S2CID   87064973 . Retrieved 19 July 2013.
  80. ↑ Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. (July 2013). "Vascularized and functional human liver from an iPSC-derived organ bud transplant". Nature. 499 (7459): 481–4. Bibcode:2013Natur.499..481T. doi:10.1038/nature12271. PMID   23823721. S2CID   4423004.
  81. ↑ Chen Y, Lüttmann FF, Schoger E, Schöler HR, Zelarayán LC, Kim KP, et al. (September 2021). "Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice". Science. 373 (6562): 1537–1540. Bibcode:2021Sci...373.1537C. doi:10.1126/science.abg5159. PMID   34554778. S2CID   237617229.
  82. ↑ Mullin E (28 January 2014). "Researchers repair retinas in mice with virus-free stem cells". fiercebiotech.com. Retrieved 17 February 2014.
  83. ↑ Park TS, Bhutto I, Zimmerlin L, Huo JS, Nagaria P, Miller D, et al. (January 2014). "Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature". Circulation. 129 (3): 359–72. doi:10.1161/CIRCULATIONAHA.113.003000. PMC   4090244 . PMID   24163065.
  84. ↑ Tang H, Sha H, Sun H, Wu X, Xie L, Wang P, et al. (October 2013). "Tracking induced pluripotent stem cells-derived neural stem cells in the central nervous system of rats and monkeys". Cellular Reprogramming. 15 (5): 435–42. doi:10.1089/cell.2012.0081. PMC   3787483 . PMID   24020696.
  85. ↑ Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, et al. (August 2014). "Chemically defined generation of human cardiomyocytes". Nature Methods. 11 (8): 855–60. doi:10.1038/nmeth.2999. PMC   4169698 . PMID   24930130.
  86. ↑ Feyen, Dries A. M.; McKeithan, Wesley L.; Bruyneel, Arne A. N.; Spiering, Sean; Hörmann, Larissa; Ulmer, Bärbel; Zhang, Hui; Briganti, Francesca; Schweizer, Michaela; Hegyi, Bence; Liao, Zhandi (21 July 2020). "Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes". Cell Reports. 32 (3): 107925. doi:10.1016/j.celrep.2020.107925. ISSN   2211-1247. PMC   7437654 . PMID   32697997.
  87. ↑ Willems E, Spiering S, Davidovics H, Lanier M, Xia Z, Dawson M, et al. (August 2011). "Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm". Circulation Research. 109 (4): 360–4. doi:10.1161/CIRCRESAHA.111.249540. PMC   3327303 . PMID   21737789.
  88. ↑ Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE (March 2011). "Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome". Nature. 471 (7337): 230–4. Bibcode:2011Natur.471..230Y. doi:10.1038/nature09855. PMC   3077925 . PMID   21307850.
  89. ↑ Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. (March 2011). "Modelling the long QT syndrome with induced pluripotent stem cells". Nature. 471 (7337): 225–9. Bibcode:2011Natur.471..225I. doi:10.1038/nature09747. PMID   21240260. S2CID   4384573.
  90. ↑ Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, et al. (February 2017). "High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells". Science Translational Medicine. 9 (377): eaaf2584. doi:10.1126/scitranslmed.aaf2584. PMC   5409837 . PMID   28202772.
  91. ↑ McKeithan, Wesley L.; Feyen, Dries A. M.; Bruyneel, Arne A. N.; Okolotowicz, Karl J.; Ryan, Daniel A.; Sampson, Kevin J.; Potet, Franck; Savchenko, Alex; Gómez-Galeno, Jorge; Vu, Michelle; Serrano, Ricardo (5 November 2020). "Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity". Cell Stem Cell. 27 (5): 813–821.e6. doi:10.1016/j.stem.2020.08.003. ISSN   1875-9777. PMC   7655512 . PMID   32931730.
  92. ↑ "iPSから心筋細胞製造 タカラバイオとベンチャー". 日本経済新聞 電子版 (in Japanese). 24 June 2014. Retrieved 8 November 2019.
  93. ↑ "iPSで心臓治療了承 高難度の再生医療へ一歩". 日本経済新聞 電子版 (in Japanese). 16 May 2018. Retrieved 8 November 2019.
  94. ↑ "ｉＰＳ細胞の心筋シート移植、臨床研究を国が大筋了承：朝日新聞デジタル". 朝日新聞デジタル (in Japanese). 16 May 2018. Archived from the original on 8 November 2019. Retrieved 8 November 2019.
  95. ↑ Wei H, Wang C, Guo R, Takahashi K, Naruse K (December 2019). "Development of a model of ischemic heart disease using cardiomyocytes differentiated from human induced pluripotent stem cells". Biochemical and Biophysical Research Communications. 520 (3): 600–605. doi: 10.1016/j.bbrc.2019.09.119 . PMID   31623826.
  96. ↑ "First transfusions of "manufactured" blood planned for 2016". Gizmag.com. 23 April 2014. Retrieved 23 April 2014.
  97. ↑ Garber K (September 2015). "RIKEN suspends first clinical trial involving induced pluripotent stem cells". Nature Biotechnology. 33 (9): 890–1. doi:10.1038/nbt0915-890. PMID   26348942. S2CID   205271169.
  98. ↑ Tobita M, Konomi K, Torashima Y, Kimura K, Taoka M, Kaminota M (June 2016). "Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine". Regenerative Therapy. 4: 78–81. doi: 10.1016/j.reth.2016.04.001 . PMC   6581824 . PMID   31245489.
  99. ↑ Riken Center for Developmental Biology. "Information on p=roposed pilot study of the safety and feasibility of transplantation of autologous hiPSC-derived retinal pigment epithelium (RPE) cell sheets in patients with neovascular age-related macular degeneration". Research. Archived from the original on 26 June 2013. Retrieved 23 July 2013.
  100. 1 2 Gallagher J (19 July 2013). "Pioneering adult stem cell trial approved by Japan". BBC News . Retrieved 23 July 2013.
  101. ↑ "First donor iPSC-derived RPE cell transplantation in AMD patient". RIKEN Center for Developmental Biology. 4 April 2017. Archived from the original on 6 September 2017. Retrieved 6 September 2017.
  102. ↑ "First serious adverse reaction to iPS-derived retinal cell transplant reported". The Japan Times Online. 17 January 2018. Archived from the original on 27 January 2018. Retrieved 27 January 2018.
  103. ↑ Deinsberger J, Reisinger D, Weber B (11 September 2020). "Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis". npj Regenerative Medicine. 5 (1): 15. doi: 10.1038/s41536-020-00100-4 . PMC   7486930 . PMID   32983575.
  104. ↑ Knoepfler P (25 January 2021). "What are induced pluripotent stem cells or IPS cells & clinical prospects?". The Niche. Retrieved 7 February 2021.
  105. 1 2 Koga K, Wang B, Kaneko S (2020). "Current status and future perspectives of HLA-edited induced pluripotent stem cells". Inflammation and Regeneration. 40: 23. doi: 10.1186/s41232-020-00132-9 . PMC   7528263 . PMID   33014207. Creative Commons by small.svg  This article incorporates textfrom this source, which is available under the CC BY 4.0 license.
  106. ↑ Haridy R (23 October 2017). "Anti-Aging Stem Cell Treatment Proves Successful in Early Human Trials". New Atlas.
  107. ↑ Sarkar TJ, Quarta M, Mukherjee S, Colville A, Paine P, Doan L, et al. (March 2020). "Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells". Nature Communications. 11 (1): 1545. Bibcode:2020NatCo..11.1545S. doi:10.1038/s41467-020-15174-3. PMC   7093390 . PMID   32210226.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.